GeoVax Gets Notice of Allowance for Cancer Vaccine Patent

 GeoVax Intellectual Property Portfolio Includes More than 70 Granted/Pending Patent Applications

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 16/068,527 entitled “Compositions and Methods for Generating an Immune Response to a Tumor Associated Antigen.” In general, the claims to be granted in the patent cover GeoVax’s vector platform for expressing tumor associated antigens in virus-like particles (VLPs) from a Modified Vaccinia Ankara (MVA) viral vector and encompass GeoVax’s Mucin 1 (MUC1) tumor-associated antigen immunotherapy candidate.

GeoVax’s initial results with its MVA-VLP-MUC1 immunotherapy candidates have been encouraging. The Company uses its MVA-VLP vaccine platform to express abnormal, aberrantly glycosylated forms of the cell surface-associated MUC1 protein that is associated with a wide range of cancers, including breast, colon, ovarian, prostate, pancreatic, and lung.

https://finance.yahoo.com/news/geovax-receives-notice-allowance-cancer-140000519.html